Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Tepkinly |
|---|---|
| Manufacturer | AbbVie Inc |
| Prescription required | Yes |
Tepkinly 4mg/0.8ml Injektionsl sung,1ST x 0.8ml(Epcoritamab)
Epcoritamab
Description
Tepkinly 4mg/0.8ml Injektionsl sung,1ST x 0.8ml(Epcoritamab) is a medicine catalog record in the MediPriceHub database. Active ingredient: Epcoritamab. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: AbbVie Inc. Therapeutic category: Medicine Library > Oncology Medicines > Lymphoma medication. Pack information: 4 / 0.8, 1. Origin country or market: Germany. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.How to Use
Use Epcoritamab under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Epcoritamab. Pack size: 4 / 0.8, 1. Pack unit: bottle. Manufacturer: AbbVie Inc. Origin country: Germany. Source category: Medicine Library > Oncology Medicines > Lymphoma medication. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.This information is for reference only. Consult a qualified healthcare professional before using any medicine.